Intermune’s Esbriet Flops In Front Of IQWiG
This article was originally published in The Pink Sheet Daily
Germany’s IQWiG remains unconvinced about the added value offered by Intermune’s Esbriet, a decision that adds to industry concerns on assessment methodology
You may also be interested in...
Amended AMNOG Sees New Life Breathed Into Trajenta Reimbursement Bid In Germany
Changes to Germany’s drug reimbursement law have permitted Boehringer Ingelheim and Eli Lilly to submit an updated dossier for their oral therapy Trajenta, giving medicine makers who operate there hope that further positive amendments will occur.
Second-Quarter Earnings Updates, In Brief
In quarterly earnings calls, GlaxoSmithKline talks acquisition strategy while Regeneron is bullish on the sales prospects for its age-related macular degeneration drug Eylea and Sanofi highlights the recently initiated Phase III ODYSSEY program in hypercholesterolemia.
Germany Issues Benefit Assessment For InterMune’s Esbriet, Despite Orphan Drug Status
Germany’s senior health technology assessment body, the G-BA, has said that InterMune’s Esbriet is beneficial, but says it is unsure to what extent. However, such added value assessments for orphan drugs could be illegal.